SYTL3

Across TCGA pan-cancer cohorts, SYTL3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SYTL3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SYTL3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SYTL3 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, HNSC, and CCRCC are the cancer types where SYTL3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SYTL3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	II,III,IV	−1.088	<.001	9	view →
HNSC	Male	III,IV	−0.682	<.001	8	view →
CCRCC	All	All	+0.449	.001	7	view →
LUAD	Male	All	−0.133	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SYTL3–LSCC

Open the LSCC breakdown →